Consistently, PI3K/AKT inhibitor LY294002 or mTOR inhibitor Rapamycin will inhibit CRC progression by aggravating KLK10 gene knockdown and inhibiting mTOR-mediated HIF-1α activation and decreasing lactate production (Table 1). The gene discussed is AKT1; the disease is colorectal carcinoma.